For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback